Mechanistic approach to the pathophysiology of target organ damage in hypertension from studies in a human model with characteristics opposite to hypertension: Bartter's and Gitelman's syndromes.
BACKGROUND
Extensive studies using Bartter's/Gitelman's syndrome patients have provided insights into the angiotensin II (Ang II) signaling pathways involved in the regulation of vascular tone and cardiovascular-renal remodeling. The renin-angiotensin-aldosterone system is activated in these syndromes, however, patients do not develop hypertension and cardiovascular remodeling and clinically manifest conditions opposite to hypertension. The short- and the long-term signaling of Ang II remains an important matter of investigation to shed light on mechanisms responsible for the pathophysiology of hypertension and its long-term complications. The long-term signaling of Ang II is involved in the pathophysiology of cardiovascular-renal remodeling and inflammatory responses in which the balance between RhoA/Rho kinase pathway and NO system plays a crucial role.


RESULTS
In this brief review, the results of our studies in Bartter's and Gitelman's syndromes are reported on these processes.


CONCLUSIONS
The information obtained from these studies can clarify, confirm or be used to extend the biochemical mechanisms responsible for the pathophysiology of hypertension and its long-term complications and could offer further chances to identify additional potential significant targets of therapy.
Department of Medicine, Nephrology and Hypertension, University of Padova, Via Giustiniani, 2, 35128, Padua, Italy. renzcalo@unipd.it.
L A
LA
Calò
Department of Medicine, Nephrology and Hypertension, University of Padova, Via Giustiniani, 2, 35128, Padua, Italy.
G
G
Maiolino
D001477:Bartter Syndrome / Q000378:metabolism*; D053579:Gitelman Syndrome / Q000378:metabolism*; D006801:Humans; D006973:Hypertension / Q000378:metabolism*
Angiotensin II signaling; Bartter’s syndrome; Cardiovascular–renal remodeling; Gitelman’s syndrome; Hypertension; Nitric oxide; Rho kinase